Biochemical assays reveal how three proteins fit together to form the channel that controls the flow of calcium ions into mitochondria.
Mitochondria are often referred to as the “powerhouses” of eukaryotic cells because they supply most of the energy that the cells need. In the 1960s it was discovered that active mitochondria, when isolated from the cell and studied “in a test-tube”, accumulate large quantities of calcium ions (Ca2+). However, the importance of this phenomenon was not immediately clear. Later, in the 1990s, it was revealed that mitochondria inside eukaryotic cells also take up Ca2+ ions (Rizzuto et al., 1998).
The uptake of Ca2+ by mitochondria stimulates certain enzymes to regulate energy production in order to match the cell’s activity. However, if too much Ca2+ enters, the mitochondria can malfunction which often kills the cell. The uptake of Ca2+ by mitochondria must therefore be tightly controlled. Now, in eLife, Christopher Miller and colleagues at Brandeis University – including Ming-Feng Tsai and Charles Phillips as joint first authors – report how this control might be achieved (Tsai et al., 2016).
Each mitochondrion has an inner membrane and an outer membrane. Small molecules and ions (including Ca2+ ions) can pass freely through the outer membrane, but not the inner one. The transport of Ca2+ through the inner membrane depends on an ion channel called the “mitochondrial Ca2+ uniporter” (or MCU channel for short). This channel is the most selective Ca2+ channel currently known (Kirichok et al., 2004).
The MCU channel is actually a protein complex made from multiple subunits. The Ca2+ ions pass through a pore-forming subunit (Baughman et al., 2011; De Stefani et al., 2011) that spans the inner membrane and is surrounded by five other subunits. These other subunits regulate the pore-forming subunit, but how they do this and how they are all assembled into the channel complex are still topics of active debate.
The pore-forming subunit plus two of the five regulatory subunits (proteins named EMRE and MICU1) form what can be referred to as the “core functional unit of the MCU” (Perocchi et al., 2010; Sancak et al., 2013). This stripped-down version of the complex acts much like the full channel and can be used to explain how mitochondria take up Ca2+. Tsai, Phillips and colleagues used biochemical assays to determine how these three subunits fit together within the core functional unit. They demonstrated that EMRE interacts with the pore-forming subunit via domains that span the inner membrane. They also found that the subunits could not form a working channel without this interaction. Furthermore, they showed that MICU1 binds to EMRE at the outer surface of the inner mitochondrial membrane (Figure 1).
Combined with relevant data from other groups (Mallilankaraman et al., 2012; Csordás et al., 2013; Patron et al., 2014), the results of Tsai, Phillips and colleagues provide a glimpse of how the MCU channel complex might work at the molecular level. EMRE anchors MICU1 near the pore-forming subunit, and MICU1 then blocks the pore when the Ca2+concentration in the cytosol is at its resting level. This stops Ca2+ ions from flowing into the mitochondria. However, when the Ca2+ concentration in the cytosol increases, Ca2+ ions bind to MICU1and cause it to dissociate from the pore to allow other Ca2+ ions to pass through (Figure 1). Thus MICU1 serves as a Ca2+-sensitive “lid” on the MCU channel complex, which closes and opens the channel in response to changes in the Ca2+ concentration in the cytosol. Notably, the pore-forming subunit cannot work without EMRE (Sancak et al., 2013). Thus it might be EMRE, and not the pore forming subunit, that controls how many of the MCU channels are active in various tissues.
Now that we know how the MCU core functional unit is assembled, the stage is set to explore how the structure of the MCU channel relates to its function. This will bring us closer to understanding the phenomenon of Ca2+ uptake by mitochondria and how it could be affected via drugs to control energy production in cells and cell death.
© 2016, Garg et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
Many photosynthetic organisms employ a CO2 concentrating mechanism (CCM) to increase the rate of CO2 fixation via the Calvin cycle. CCMs catalyze ≈50% of global photosynthesis, yet it remains unclear which genes and proteins are required to produce this complex adaptation. We describe the construction of a functional CCM in a non-native host, achieved by expressing genes from an autotrophic bacterium in an Escherichia coli strain engineered to depend on rubisco carboxylation for growth. Expression of 20 CCM genes enabled E. coli to grow by fixing CO2 from ambient air into biomass, with growth in ambient air depending on the components of the CCM. Bacterial CCMs are therefore genetically compact and readily transplanted, rationalizing their presence in diverse bacteria. Reconstitution enabled genetic experiments refining our understanding of the CCM, thereby laying the groundwork for deeper study and engineering of the cell biology supporting CO2 assimilation in diverse organisms.
Since the 1960s, a single class of agent has been licensed targeting virus-encoded ion channels, or ‘viroporins’, contrasting the success of channel blocking drugs in other areas of medicine. Although resistance arose to these prototypic adamantane inhibitors of the influenza A virus (IAV) M2 proton channel, a growing number of clinically and economically important viruses are now recognised to encode essential viroporins providing potential targets for modern drug discovery. We describe the first rationally designed viroporin inhibitor with a comprehensive structure-activity relationship (SAR). This step-change in understanding not only revealed a second biological function for the p7 viroporin from hepatitis C virus (HCV) during virus entry, but also enabled the synthesis of a labelled tool compound that retained biological activity. Hence, p7 inhibitors (p7i) represent a unique class of HCV antiviral targeting both the spread and establishment of infection, as well as a precedent for future viroporin-targeted drug discovery.